SBIR/STTR Research Award
Proteomic analysis during stem cell differentiation
Award amount
$99,498Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- BIOTRACES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (Applicant's Description Verbatim): Stem cells are defined as cells
with the ability both to self renew and to differentiate. This property of stem
cells underpins growth and differentiation during development and sustains
homeostasis and repair processes throughout adult life. The identification of
novel proteins that drive pluriopotent stem cell growth or factors that direct
their differentiation and lineage commitment, are of fundamental significance
in the understanding of stem cell biology and its medical applications. Central
to the identification and characterization of these proteins is the
availability of a super sensitive method for studying the protein expression
profile of these cells under a wide range of conditions in a sensitive,
quantitative, and efficient fashion. Alas, the prior-art techniques of
differential display of proteins arc not sensitive enough and their dynamic
detection range is not adequate for studying low abundance proteins. BIOTRACES
has developed a proprietary Multi Photon Detection (MPD) technology. Using MPD
technology, we are developing an integrated proteomic system including the MPD
Imager for differential display of protein that is at least one hundred times
more sensitive than other techniques. The purpose of this Phase I proposal is
to apply MPD-based proteomics tools to identify and characterize proteins that
are differentially modified or expressed during hematopoietic stem cells
lineage commitment and differentiation.
PROPOSED COMMERCIAL APPLICATION:
MPD has successfully been applied to RNA/DNA analysis, immunoassays and proteomics.
The MPD-enhanced analysis of proteins, including better immunoassays for cytokines will
enable better biomedical diagnostics and new therapeutic modalities. This is a large, multi-
billion dollar/yr market. BioTraces may become a dominant player in part of this market with
income estimated to be in the range of 100-200 million dollars annually. We are developing
MPD enabled ultrasensitive protein-chips, including the P-chip for stem cells. These new
techniques permit us to capture a considerable segment of diagnostic proteomics and
diagnostic oncology market.
Technology keywords
Not reported